Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains the leading cause of death globally and a significant contributor to rising healthcare expenditures in the United States. For employers and health plans, the financial burden includes not only direct medical costs but also indirect costs from absenteeism and reduced productivity. By leveraging artificial intelligence and genetic-epigenetic technology, Cardio Diagnostics aims to shift the focus from reactive treatment to proactive prevention. The company's tests, such as Epi+Gen CHD, provide a personalized risk score that can guide early interventions, potentially reducing the incidence of heart attacks and strokes.
The upcoming conferences offer a platform for Cardio Diagnostics to demonstrate how its HeartRisk population insights platform can aggregate de-identified data to help plan sponsors identify high-risk groups and tailor wellness programs. This data-driven approach could enable more efficient allocation of resources, targeting interventions to those who need them most. According to the company, early detection and management of cardiovascular risk factors can lead to better health outcomes and lower costs over time.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. For more information, visit the company's newsroom at https://ibn.fm/CDIO.
The full press release is available at https://ibn.fm/qFRHu. Investors should review the company's filings with the SEC for a complete understanding of risks and forward-looking statements, including those described in the most recent Annual Report on Form 10-K and subsequent quarterly reports.
